48604 20210121114458.0 sideral 94411 ART-2015-94411 eng Oteo, J Prospective multicenter study of carbapenemase-producing Enterobacteriaceae from 83 hospitals in Spain reveals high in vitro susceptibility to colistin and meropenem 2015 Access copy available to the general public Unrestricted The aim of this study was to determine the impact of carbapenemase-producing Enterobacteriaceae (CPE) in Spain in 2013 by describing the prevalence, dissemination, and geographic distribution of CPE clones, and their population structure and antibi- otic susceptibility. From February 2013 to May 2013, 83 hospitals (about 40,000 hospital beds) prospectively collected nondupli- cate Enterobacteriaceae using the screening cutoff recommended by EUCAST. Carbapenemase characterization was performed by phenotypic methods and confirmed by PCR and sequencing. Multilocus sequencing types (MLST) were determined for Kleb- siella pneumoniae and Escherichia coli. A total of 702 Enterobacteriaceae isolates met the inclusion criteria; 379 (54%) were CPE. OXA-48 (71.5%) and VIM-1 (25.3%) were the most frequent carbapenemases, and K. pneumoniae (74.4%), Enterobacter cloacae (10.3%), and E. coli (8.4%) were the species most affected. Susceptibility to colistin, amikacin, and meropenem was 95.5%, 81.3%, and 74.7%, respectively. The most prevalent sequence types (STs) were ST11 and ST405 for K. pneumoniae and ST131 for E. coli. Forty-five (54.1%) of the hospitals had at least one CPE case. For K. pneumoniae, ST11/OXA-48, ST15/OXA-48, ST405/ OXA-48, and ST11/VIM-1 were detected in two or more Spanish provinces. ST11 isolates carried four carbapenemases (VIM-1, OXA-48, KPC-2, and OXA-245), but ST405 isolates carried OXA-48 only. A wide interregional spread of CPE in Spain was ob- served, mainly due to a few successful clones of OXA-48-producing K. pneumoniae (e.g., ST11 and ST405). The dissemination of OXA-48-producing E. coli is a new finding of public health concern. According to the susceptibilities determined in vitro, most of the CPE (94.5%) had three or more options for antibiotic treatment. info:eu-repo/grantAgreement/ES/FIS/PI12-01242 info:eu-repo/semantics/openAccess All rights reserved http://www.europeana.eu/rights/rr-f/ 4.415 2015 PHARMACOLOGY & PHARMACY 34 / 255 = 0.133 2015 Q1 T1 MICROBIOLOGY 22 / 123 = 0.179 2015 Q1 T1 2.343 2015 Infectious Diseases 2015 Q1 Pharmacology (medical) 2015 Q1 Pharmacology 2015 Q1 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Ortega, A Bartolomé, R Bou, G Conejo, C Fernández-Martínez, M González-López, JJ Martínez-García, L Martínez-Martínez, L Merino, M Miró, E Mora, M Navarro, F Oliver, A Pascual, A Rodríguez-Baño, J Ruiz-Carrascoso, G Ruiz-Garbajosa, P Zamorano, L Bautista, V Pérez-Vázquez, M Campos, J on behalf of GEIH-GEMARA (SEIMC) and REIPI 59, 6 (2015), 3406-3412 Antimicrob. agents chemother. Antimicrobial Agents and Chemotherapy 0066-4804 823972 http://zaguan.unizar.es/record/48604/files/texto_completo.pdf Versión publicada 127317 http://zaguan.unizar.es/record/48604/files/texto_completo.jpg?subformat=icon icon Versión publicada oai:zaguan.unizar.es:48604 articulos driver 2021-01-21-10:49:19 ARTICLE